NCT07529535 2026-04-17
A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1 Suspended
Zhejiang Anglikang Pharmaceutical Co., Ltd.
T-ACE Medical Co., Ltd
Curis, Inc.